Skip to main content
Triangle logo TriangleGet started

Loncastuximab Tesirine (NCT06788964)

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL): a one-minute explainerNCT067889641 min

Loncastuximab Tesirine trial for Relapsed or Refractory Large B-cell Lymphoma (NCT06788964). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with eligible large B-cell lymphomas that relapsed or resisted treatment after at least one regimen. They must need bridging treatment before planned commercial CD19 CAR-T therapy. Previous CD19-directed treatment is excluded.

The idea: use loncastuximab tesirine to deliver a DNA-damaging payload to CD19-bearing cells, alongside rituximab targeting CD20. Infusions repeat every three weeks for 1–6 cycles before CAR-T. Researchers assess response, low blood counts and infections afterward.

This phase 2 study plans 29 patients. Narendranath Epperla leads at Huntsman in Salt Lake City, with two recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.